Skip to main content

Table 2 Correlations between serum levels of BAFF and anti-Jo-1 antibodies with serum levels of muscle enzymes (CK and AST), myoglobin, and CRP at baseline evaluation in myositis patients and in subgroups with dermatomyositis/polymyositis, with or without lung involvement, and in patients with short disease duration

From: Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

   anti-Jo-1 CK Myoglobin AST CRP
r p r p r p r p r p
All (n = 63) BAFF 0.42 0.0006** 0.50 < 0.0001*** 0.39 0.004* 0.45 0.0003** 0.44 0.0004**
anti-Jo-1 0.47 0.0001*** 0.46 0.0006** 0.28 0.03 0.38 0.003*
PM (n = 41) BAFF 0.43 0.005* 0.63 < 0.0001*** 0.42 0.01 0.43 0.006* 0.48 0.002*
anti-Jo-1 0.44 0.004* 0.46 0.006* 0.18 0.26 0.41 0.01
ILD (n = 48) BAFF 0.38 0.008 0.49 < 0.0001*** 0.40 0.01 0.46 0.001* 0.44 0.003*
anti-Jo-1 0.49 < 0.0001*** 0.58 < 0.0001*** 0.30 0.04 0.47 0.001*
Early (n = 30) BAFF 0.57 0.001* 0.63 0.0002** 0.55 0.0025* 0.61 0.0003** 0.41 0.03
anti-Jo-1 0.69 < 0.0001*** 0.74 < 0.0001*** 0.56 0.001* 0.34 0.06
  1. AST aspartate aminotransferase, BAFF B-cell activating factor of the tumour necrosis factor family, CK creatine kinase, CRP C-reactive protein, Early early case, defined as duration up to 6 months from diagnosis, ILD interstitial lung disease, PM polymyositis
  2. p = p value; *alfa = 0.05 (0.006 after Bonferroni correction); **alfa = 0.01 (0.001 after Bonferroni correction); ***alfa = 0.001 (0.0001 after Bonferroni correction)